As a new anti-tumor protein drug, rhCNB can activate the innate immune system through the TLR4/NF-κB signaling pathway, promote the maturation of dendritic cells, upregulate the expression of macrophages, and induce tumor cell apoptosis [4]. Here, NFKB1 is linked to neoplasm.